SAN FRANCISCO and HERZLIYA, Israel, Jan. 3, 2019 /PRNewswire/ -- 89bio, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders, today announced the appointment of Hank Mansbach, M.D., as chief medical officer.  Dr.

-Investment round led by founding investors, OrbiMed Israel and OrbiMed US, and Longitude Capital, with participation by RA Capital Management and Pontifax- -Company acquires NASH assets from Teva, initiates Phase 1 clinical trial- -Rohan Palekar, former Avanir Pharmaceuticals CEO, joins 89Bio as